First Patients Treated in a Prostate Cancer Trial
Generex Biotechnology has treated the first prostate cancer patients with the company’s novel peptide vaccine in a Phase I trial.
The trial is being conducted as an extension of a collaborative agreement between Generex’s Antigen Express and the Saint Savas Cancer Hospital. In addition to safety, the study will seek to establish specific immunological responses to the AE37 vaccine peptide in 30 patients.
Though the study is not designed to test efficacy, imaging and prostate specific antigen levels will be monitored to assess tumor status, Generex said.